Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

• Status: Completed
• Trial end date: 2016-11-11
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Evolocumab; Hydroxymethylglutaryl-CoA Reductase Inhibitors

Criteria

Inclusion Criteria:

• Randomized into Study 20110118 (FOURIER; NCT01764633)

Exclusion Criteria:

• Current or known past diagnosis of dementia or mild cognitive impairment (MCI)